Distribution, Pharmacokinetics and Extent of Sensory Blockade in ESP Blocks



Status:Not yet recruiting
Healthy:No
Age Range:18 - 60
Updated:3/17/2019
Start Date:July 2019
End Date:November 2020
Contact:Sanjib Adhikary, MD
Email:sadhikary1@pennstatehealth.psu.edu
Phone:717-531-6140

Use our guide to learn which trials are right for you!

A Volunteer Study to Determine the Anatomical Distribution of Injectate, the Extent of Sensory Block, and the Pharmacokinetics of Ropivacaine Following Erector Spinae Plane (ESP) Blocks.

The primary objectives of this study are to define the extent of dermatomal anesthesia and
anatomical spread of injectate (as defined by MRI imaging) that is provided by an ESP block
at the T5 level, using twenty milliliters of 0.5% ropivacaine.

The secondary objectives include: 1) the measurement of changes in hemodynamic parameters
associated with the ESP block, 2) the duration of sensory effects provided by ropivacaine
with or without epinephrine, 3) the venous plasma concentration of ropivacaine associated at
various time intervals after completion of the ESP block.


Inclusion Criteria:

- Healthy adults aged 18 to 60 inclusive

- Weight between 60 and 100 kg inclusive

- Height 160 to190 cm inclusive

Exclusion Criteria:

- Pregnant females

- Chronic medical condition requiring medication

- History of previous major spinal, abdominal or thoracic surgery

- Congenital abnormalities of the spine, back, thorax or abdomen

- History of major trauma to the thorax or abdomen;

- Allergy to ropivacaine or other amide local anesthetics

- The presence of any metallic implant in their body

- Any contraindication to magnetic resonance imaging as determined by completion of a
standard questionnaire administered to all patients undergoing magnetic resonance
imaging.

- Allergy to Gadolinium radiological contrast agent.
We found this trial at
1
site
Hershey, Pennsylvania 17033
Phone: 717-531-0003
?
mi
from
Hershey, PA
Click here to add this to my saved trials